ENDPOINTS

Boehringer's bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M

Last month

News Briefing

Argenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of staff

Last month

News Briefing

Idorsia’s blood pressure pill no longer requires a REMS; Solu raises $41M

Last month

News Briefing

Rallybio ends development in rare disorder; ImmunityBio raises $75M

Last month

News Briefing

Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers

Last month

News Briefing

Sarepta indicates it's safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTx

Last month

News Briefing

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Last month

News Briefing

Prazer Therapeutics raises $20M; Carisma lets go of most staff

Last month

News Briefing

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

Last month

News Briefing

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

Last month

News Briefing

Nkarta to lay off 34% of staff; Savara’s debt financing deal

Last month

News Briefing

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer

2 months ago

News Briefing

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

2 months ago

News Briefing

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

2 months ago

News Briefing

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

2 months ago

News Briefing

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

2 months ago

Peer Review

Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding

2 months ago

News Briefing

Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms

2 months ago

News Briefing

Vertanical’s Phase 3 win for non-opioid painkiller; Apriori lays off 40% of staff

2 months ago

News Briefing

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

2 months ago

News Briefing

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

2 months ago

News Briefing

Corrected: Mineralys aims to raise $250M; Coherus' staffing changes

2 months ago

News Briefing

CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis

2 months ago

News Briefing

Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADC

2 months ago

News Briefing

about the author

author articles

Boehringer's bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M

Argenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of staff

Idorsia’s blood pressure pill no longer requires a REMS; Solu raises $41M

Rallybio ends development in rare disorder; ImmunityBio raises $75M

Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers

Sarepta indicates it's safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTx

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Prazer Therapeutics raises $20M; Carisma lets go of most staff

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

Nkarta to lay off 34% of staff; Savara’s debt financing deal

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding

Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms

Vertanical’s Phase 3 win for non-opioid painkiller; Apriori lays off 40% of staff

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

Corrected: Mineralys aims to raise $250M; Coherus' staffing changes

CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis

Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADC